ERBB2 and breast carcinoma: Jitawatanarat et al. [16] evaluated the tolerability and cardiac safety of docetaxel, cyclophosphamide, and trastuzumab (TCyH) for the treatment of early-stage human epidermal growth factor receptor-2 (HER2)-positive breast cancer and compared the standard trastuzumab-based chemotherapy regimens doxorubicin with cyclophosphamide followed by paclitaxel and trastuzumab (ACTH) and docetaxel, carboplatin, and trastuzumab (TCaH).